anifrolumab sold brand name saphnelo monoclonal antibody used treatment systemic lupus erythematosus binds type interferon receptor blocking activity type interferons interferonα interferonβmedical citation needed anifrolumab approved medical use united states july european union february us food drug administration considers firstinclass systemic lupus erythematosus body produce great amount type interferon activates immune system excessively creates problems lupus patients anifrolumab acts block sending signals immune cells prevents body attacked common adverse effect shingles occurred patients lowdose group highdose group placebo group overall adverse effect rates comparable drug developed medimmune unit astrazeneca chose move anifrolumab instead sifalimumab phase iii trials lupus december committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product saphnelo intended treatment moderate severe systemic lupus erythematosus applicant medicinal product astrazeneca anifrolumab approved medical use european union february anifrolumab international nonproprietary name immune activation dostarlimab ibalizumab httpsenwikipediaorgwikianifrolumab